<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">738</article-id><article-id pub-id-type="doi">10.17650/2949-5857-2024-14-3-43-51</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prognosis of early and advanced signet ring cell gastric carcinoma compared with other histological subtypes</article-title><trans-title-group xml:lang="ru"><trans-title>Прогноз при раннем и распространенном перстневидноклеточном раке желудка в сравнении с другими гистологическими</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-9711-5620</contrib-id><name-alternatives><name xml:lang="en"><surname>Torosyan</surname><given-names>R. O.</given-names></name><name xml:lang="ru"><surname>Торосян</surname><given-names>Р. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Rafael Oganesovich Torosyan </bold></p><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><bold>Рафаэль Оганесович Торосян </bold></p><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><email>rf.torosyan97@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5403-2396</contrib-id><name-alternatives><name xml:lang="en"><surname>Nered</surname><given-names>S. N.</given-names></name><name xml:lang="ru"><surname>Неред</surname><given-names>С. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522,</italic></p><p><italic>2/1 Barricadnaya St., Moscow 123995</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24,</italic></p><p><italic>123995 Москва, ул. Баррикадная, 2/1</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3852-3969</contrib-id><name-alternatives><name xml:lang="en"><surname>Kozlov</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Козлов</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5574-0047</contrib-id><name-alternatives><name xml:lang="en"><surname>Sun</surname><given-names>Henian</given-names></name><name xml:lang="ru"><surname>Сунь</surname><given-names>Хэнянь</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4744-6141</contrib-id><name-alternatives><name xml:lang="en"><surname>Kononets</surname><given-names>P. V.</given-names></name><name xml:lang="ru"><surname>Кононец</surname><given-names>П. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5229-8203</contrib-id><name-alternatives><name xml:lang="en"><surname>Stilidi</surname><given-names>I S.</given-names></name><name xml:lang="ru"><surname>Стилиди</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522,</italic></p><p><italic>1 Ostrovityanova St., Moscow 11799</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24,</italic></p><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-09-12" publication-format="electronic"><day>12</day><month>09</month><year>2024</year></pub-date><volume>14</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>51</lpage><history><date date-type="received" iso-8601-date="2024-09-12"><day>12</day><month>09</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-09-12"><day>12</day><month>09</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, ABV-press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, АБВ-пресс</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">ABV-press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://onco-surgery.info/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/738">https://onco-surgery.info/jour/article/view/738</self-uri><abstract xml:lang="en"><p><bold>Background.</bold><bold> </bold>Signet ring cell gastric carcinoma of the stomach traditionally characterized by its poor prognosis. Survival of patients with signet ring cell gastric carcinoma regardless of the stage of the disease has not been well studied.</p><p><bold>Aim.</bold><bold> </bold>To compare clinicopathological characteristics and survival of the patients with signet ring cell gastric carcinoma of the stomach and non-signet ring cell carcinoma depending on the stage of the disease.</p><p><bold>Materials and methods. </bold>We performed retrospective review was undertaken of patients with gastric cancer who received surgical treatment in period from 2013–2018.</p><p><bold>Results. </bold>At early signet ring cell cancer, the 3and 5-year survival rates was 100,0 and 89.0 %; for non-signet ring cell carcinoma 91.4 and 85.3 % (<italic>р</italic><italic> </italic>= 0.6; Hazard Ratio (HR) 0.73; 95 % Confidence Interval (CI) 0.22–2.42) respectively. For advanced signet ring cell carcinoma, the median survival rates, 3and 5-year survival rates was 38 months, 53.0 and 38.4 %; for non-signet ring cell carcinoma 51.1 months, 59.2 and 48.0 % (<italic>р</italic><italic> </italic>= 0.2; HR 1.2; 95 % CI 0.91–1.54).</p><p><bold>Conclusion. </bold>Long-term results in patients with early (T1) signet ring cell cancer of the stomach did not significantly differ in comparison with other histological types of gastric cancer. Long-term results of advanced signet ring cell cancer are worse than non-signet ring cell cancer, but the differences are not statistically significant.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Перстневидноклеточный рак желудка традиционно относится к прогностически неблагоприятному гистологическому подтипу злокачественных новообразований желудка, однако выживаемость больных с данным видом рака в зависимости от стадии заболевания изучена недостаточно.</p><p><bold>Цель исследования </bold>– изучить клинико-морфологические характеристики и провести сравнительную оценку выживаемости больных перстневидноклеточным и неперстневидноклеточным раком желудка в зависимости от стадии заболевания.</p><p><bold>Материалы и методы. </bold>Проведен ретроспективный анализ данных 993 пациентов, получивших хирургическое лечение по поводу рака желудка в период с 2013 по 2018 г. В исследование были включены больные ранним и распространенным раком желудка перстневидноклеточной и неперстневидноклеточной морфологии согласно классификации Всемирной организации здравоохранения.</p><p><bold>Результаты. </bold>При раннем (T1a и T1b) перстневидноклеточном раке показатели 3и 5-летней выживаемости составили 100 и 89 %, при неперстневидноклеточном раке – 91,4 и 85,3 % соответственно (отношение рисков (ОР) 0,73; 95 % доверительный интервал (дИ) 0,22–2,42; <italic>p </italic>= 0,6). При распространенном перстневидноклеточном раке медиана выживаемости составила 38 мес, при неперстневидноклеточном раке – 51,1 мес, 59,2 и 48,0 % (ОР 1,2; 95 % дИ 0,91–1,54; <italic>p </italic>= 0,2).</p><p><bold>Заключение. </bold>Отдаленные результаты у больных ранним (T1) перстневидноклеточным раком желудка существенно не различались в сравнении с другими гистологическими формами. При распространенном перстневидноклеточном раке отдаленные результаты хуже, чем при неперстневидноклеточном раке, однако различия статистически недостоверны.</p></trans-abstract><kwd-group xml:lang="en"><kwd>signet ring cell carcinoma</kwd><kwd>early gastric cancer</kwd><kwd>surgery</kwd><kwd>prognosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>перстневидноклеточный рак желудка</kwd><kwd>ранний рак желудка</kwd><kwd>хирургия</kwd><kwd>прогноз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Mariette C., Carneiro F., Grabsch H.I. et al.; European Chapter of International Gastric Cancer Association. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer 2019;22(1):1–9. DOI: 10.1007/s10120-018-0868-0</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nagtegaal I.D., Odze R.D., Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76(2):182–8. DOI: 10.1111/his.13975</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Otsuji E., Yamaguchi T., Sawai K., Takahashi T. Characteristics of signet ring cell carcinoma of the stomach. J Surg Oncol 1998;67:216–20. DOI: 10.1002/(sici)1096-9098(199804)67:43.0.co;2-b</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Guo Q., Wang Y., An J. et al. A prognostic model for patients with gastric signet ring cell carcinoma. Technology in cancer research &amp; treatment. 2021;20:15330338211027912. DOI: 10.1177/15330338211027912</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Pernot S., Voron T., Perkins G. et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol 2015;21(40):11428–38. DOI: 10.3748/wjg.v21.i40.11428</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a hiato-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49. DOI: 10.1111/apm.1965.64.1.31</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nakamura K., Sugano H.,Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan 1968;59(3):251–8. PMID: 5726267</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Li Y., Zhu Z., Ma F., Xue L., Tian Y. Gastric signet ring cell carcinoma: current management and future challenges. Cancer Manag Res 2020;12:7973–81. DOI: 10.2147/cmar.s268032</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Piessen G.,Messager M.,Leteurtre E. et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 2009;250(6):878–87. DOI: 10.1097/SLA.0b013e3181b21c7b</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhang C., Liu R., Zhang W.-H. et al. Difference between signet ring cell gastric cancers and non-signet ring cell gastric cancers: a systematic review and meta-analysis. Front Oncol 2021;11:618477. DOI: 10.3389/fonc.2021.618477</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zhao S., Lv L., Zheng K. et al. Prognosis and biological behavior of gastric signet-ring cell carcinoma better or worse: a metaanalysis. Front Oncol 2021;11:603070. DOI: 10.3389/fonc.2021.603070</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Li C., Kim S., Lai J.F. et al. Advanced gastric carcinoma with signet ring cell histology. Oncology 2007;72(1–2):64–8. DOI: 10.1159/000111096</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Yokota T., Kunii Y., Teshima S. et al. Signet ring cell carcinoma of the stomach: a clinicopathological comparison with the other histological types. Tohoku J Exp Med 1998;186(2):121–30. DOI: 10.1620/tjem.186.121</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Maehara Y., Sakaguchi Y., Moriguchi S. et al. Signet ring cell carcinoma of the stomach. Cancer 1992;69(7):1645–50. DOI: 10.1002/1097-0142(19920401)69:73.0.co;2-x</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kunisaki C., Shimada H., Nomura M. et al. Therapeutic strategy for signet ring cell carcinoma of the stomach. Br J Surg 2004;91(10):1319–24. DOI: 10.1002/bjs.4637</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kim D.Y., Park Y.K., Joo J.K. et al. Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg 2004;74(12):1060–4. DOI: 10.1111/j.1445-1433.2004.03268.x</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lai Y., Xie J., Yin X.et al. Survival outcome of gastric signet ring cell carcinoma based on the optimal number of examined lymph nodes: a nomogram- and machine-learning-based approach. J Clin Med 2023;12(3):1160. DOI: 10.3390/jcm12031160</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Taghavi S., Jayarajan S.N., Davey A., Willis A.I. Prognostic significance of signet ring gastric cancer. J Clin Oncol 2012;30(28):3493–8. DOI: 10.1200/jco.2012.42.6635</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kim J.P., Kim S.C., Yang H.K. Prognostic significance of signet ring cell carcinoma of the stomach. Surg Oncol 1994;3(4):221–7. DOI: 10.1016/0960-7404(94)90037-x</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Li C., Kim S., Lai J.F. et al. Advanced gastric carcinoma with signet ring cell histology. Oncology 2007;72(1–2):64–8. DOI: 10.1159/000111096</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Yun-He Tang, Lin-Lin Ren, Tao Mao. Update on diagnosis and treatment of early signet-ring cell gastric carcinoma: a literature review. World J Gastrointest Endosc 2023;15(4):240–7. DOI: 10.4253/wjge.v15.i4.240</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Otsuji E., Yamaguchi T., Sawai K., Takahashi T. Characterization of signet ring cell carcinoma of the stomach. J Surg Oncol 1998;67(4):216–20. DOI: 10.1002/(sici)1096-9098(199804)67:43.0.co;2-b</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Hyung W.J., Noh S.H., Lee J.H. et al. Early gastric carcinoma with signet ring cell histology. Cancer 2002;94(1):78–83. DOI: 10.1002/cncr.10120</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Jin X., Wu W., Zhao J. et al. Clinical features and risk factors for lymph node metastasis in early signet ring cell gastric cancer. Front Oncol 2021;11:630675. DOI: 10.3389/fonc.2021.630675</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Kang S.H., Kim J.S., Moon H.S. et al. Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky? Medicine (Baltimore) 2017;96(33):e7532. DOI: 10.1097/MD.0000000000007532</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ninomiya Y.,Yanagisawa A., Kato Y.,Tomimatsu H. Unrecognizable intramucosal spread of diffuse-type mucosal gastric carcinomas of less than 20 mm in size. Endoscopy 2000;32(8):604–8. DOI: 10.1055/s-2000-16506</mixed-citation></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Zvezda S.A., Fedorov N.M., Tamrazov R.I. et al. Morbidity and mortality of gastric signet ring cell carcinoma in the Tyumen region in 10 years period. Khirurgiya i onkologiya = Surgery and Oncology 2024;14(2):63–72. (In Russ.). DOI: 10.17650/2949-5857-2024-14-2-63-72</mixed-citation><mixed-citation xml:lang="ru">Звезда С.А., Федоров Н.М., Тамразов Р.И. и др. Заболеваемость и смертность от перстневидноклеточного рака желудка в Тюменской области: анализ 10-летнего периода наблюдений. Хирургия и онкология 2024;14(2):63–72. DOI: 10.17650/2949-5857-2024-14-2-63-72</mixed-citation></citation-alternatives></ref></ref-list></back></article>
